- Palisade Bio ( NASDAQ: PALI ) said on Wednesday the first patient had been screened in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery.
- The company said it was working to enroll patients and expects to complete enrollment within the next 18-24 months.
- The drug LB1148 is being developed for administration before the surgeries.
- The trial is set to enroll about 600 patients and will assess the safety and efficacy of LB1148. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery.
- ( PALI ) rose 1.3% before the bell.
For further details see:
Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function